Acrux Ltd
ACR
Company Profile
Business description
Acrux Ltd is a specialty pharma company that develops and commercialises specialty and generic, transdermal and topical pharmaceuticals. Its products include creams, gels, and sprays formulated for topical and transdermal drug delivery. The company operates as a single operating segment, which derives revenue from developing and commercialising pharmaceutical products. Its geographical segments are Australia, Europe and other countries, and the United States. The majority of revenue is derived from Australia.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
36
Stocks News & Analysis
stocks
Overvalued ASX share has overly ambitious profit target
We think the new profit target is aggressive and unlikely to be met.
stocks
7 undervalued US stocks that crushed earnings
Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks
Undervalued ASX share hitting on all cylinders
Strong performance across all segments in latest earnings release.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.40 | 39.10 | -0.42% |
| CAC 40 | 8,352.00 | 16.91 | -0.20% |
| DAX 40 | 26,598.64 | 151.31 | -0.57% |
| Dow JONES (US) | 51,608.17 | 739.38 | -1.41% |
| FTSE 100 | 10,881.55 | 21.01 | -0.19% |
| HKSE | 23,753.84 | 116.24 | 0.49% |
| NASDAQ | 24,509.76 | 626.52 | -2.49% |
| Nikkei 225 | 59,662.02 | 1,480.33 | -2.42% |
| NZX 50 Index | 14,260.85 | 42.92 | -0.30% |
| S&P 500 | 7,416.59 | 145.08 | -1.92% |
| S&P/ASX 200 | 9,044.70 | 37.50 | -0.41% |
| SSE Composite Index | 3,602.57 | 31.78 | -0.87% |